---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295267847.md"
description: "ANI Pharmaceuticals shares are trading lower despite reporting better-than-expected Q2 results, possibly dragged down by lowered Cortrophin outlook, margin compression, and rising costs."
datetime: "2026-08-07T18:26:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295267847.md)
  - [en](https://longbridge.com/en/news/295267847.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295267847.md)
generator: "portal-rs"
---

# 

ANI Pharmaceuticals shares are trading lower despite reporting better-than-expected Q2 results, possibly dragged down by lowered Cortrophin outlook, margin compression, and rising costs.

### Related Stocks

- [ANIP.US](https://longbridge.com/en/quote/ANIP.US.md)

## Related News & Research

- [ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2026 Earnings Guidance](https://longbridge.com/en/news/295227182.md)
- [These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results](https://longbridge.com/en/news/295423642.md)
- [CRMD: Diversified portfolio, strong cash flow, and new market opportunities drive growth and expansion](https://longbridge.com/en/news/298491477.md)
- [ANI Pharma CEO Nikhil Lalwani disposes of 5,400 common shares worth $401,220](https://longbridge.com/en/news/297093829.md)
- [ANI Pharma SVP, CFO Stephen P. Carey sells 2,850 shares for $207,480](https://longbridge.com/en/news/297704077.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**